Accelerate the advancement of intelligent regulation in pharmaceutical production—strengthen regulatory efforts through public-private collaboration.

Release date:

2021-04-30

On the morning of April 30, 2021, at the invitation of the Guangxi Administration for Drug Supervision, Guo Xiong, General Manager of Baihui Pharmaceutical, along with Lin Qiaohui, Head of Quality Assurance, and their delegation, attended the "Research Collaboration Communication Meeting" organized by the Drug Review and Inspection Center of the Guangxi Administration for Drug Supervision. They were accompanied by leaders including Jiang Shoujun, Director of the Drug Review and Inspection Center; Lu Shihua, Chief of the Section; and Gan Yongqi, Deputy Director of the Microbiology Department at the Guangxi Institute for Food and Drug Control.

2021 Year 4 Month 30 On the morning of the day, at the invitation of the Guangxi Administration for Drug Supervision, Guo Xiong, General Manager of Baihui Pharmaceutical, along with Lin Qiaohui, Head of Quality, and their delegation, attended the "Research Collaboration Communication Meeting" hosted by the Drug Review and Inspection Center of the Guangxi Administration for Drug Supervision. They were accompanied by leaders including Jiang Shoujun, Director of the Drug Review and Inspection Center; Lu Shihua, Chief of the Section; and Gan Yongqi, Deputy Director of the Microbiology Department at the Guangxi Institute for Food and Drug Control.

At the meeting, Director Jiang Shoujun first introduced the purpose and content of this conference. He emphasized that, in order to develop and establish a more standardized and efficient pharmaceutical regulatory model, Guangxi is building an intelligent drug supervision platform. This platform will enable smart, IT-driven oversight across all stages—ranging from supplier management and procurement-to-inspection processes, to production control, product warehousing, and sales—thereby promoting standardized enterprise practices, enhancing third-party drug inspection and early warning systems, and ultimately integrating comprehensive services for pharmaceutical regulation.

Both parties have reached a preliminary agreement on collaborative efforts toward intelligent supervision of pharmaceutical production. As a pilot enterprise, Baihui Pharmaceutical will gradually enhance the information technology infrastructure of its quality management system, jointly fostering the healthy development of pharmaceutical manufacturing and intelligent regulatory practices in Guangxi.

More than 100 students from Guangxi University's School of Medicine visited Baihui Pharmaceutical.

Guangxi University's College of Chemical Engineering Holds Project Exchange Meeting with Baihui Pharmaceutical